Орфанні ендокринні захворювання: сучасні тенденції хірургічного лікування в Україні

Особливості поточного стану діагностики та терапії рідкісних ендокринних захворювань. Дослідження ендокринних орфанних захворювань, що потребують хірургічного лікування. Лікування аденом гіпофіза, характеристика головних видів хірургічного втручання.

Рубрика Медицина
Вид статья
Язык украинский
Дата добавления 28.12.2023
Размер файла 51,7 K

Отправить свою хорошую работу в базу знаний просто. Используйте форму, расположенную ниже

Студенты, аспиранты, молодые ученые, использующие базу знаний в своей учебе и работе, будут вам очень благодарны.

23. Bausch B, Borozdin W, Mautner VF, Hoffmann MM, Boehm D, Robledo M, et al. Germline NF1 mutational spectra and loss-of- heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab. 2007 Jul;92(7):2784-92. doi: 10.1210/jc.2006-2833.

24. Hari Kumar KV, Shaikh A, Sandhu AS, Prusty P. Neurofibromatosis

1 with pheochromocytoma. Indian J Endocrinol Metab. 2011 Oct;15 Suppl 4(Suppl4):S406-S408. doi: 10.4103/2230-8210.86988.

25. Corral de la Calle MA, Encinas de la Iglesia J, Fernandez-Perez GC, Repolles Cobaleda M, Fraino A. Adrenal pheochromocytoma: keys to radiologic diagnosis. Radiologia (Engl Ed). 2022 Jul- Aug;64(4):348-67. doi: 10.1016/j.rxeng.2022.07.002.

26. Gimenez-Roqueplo AP, Caumont-Prim A, Houzard C, Hignette C, Hernigou A, Halimi P, et al. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. J Clin Endocrinol Metab. 2013 Jan;98(1):E162- E173. doi: 10.1210/ jc.2012-2975.

27. Bachinski LL, Olufemi SE, Zhou X, Wu CC, Yip L, Shete S, et al. Genetic mapping of a third Li-Fraumeni syndrome predisposition locus to human chromosome 1q23. Cancer Res. 2005 Jan 15;65(2):427-31.

28. Salpea P, Stratakis CA. Carney complex and McCune Albright syndrome: an overview of clinical manifestations and human molecular genetics. Mol Cell Endocrinol. 2014 Apr 5;386(1-2):85- 91. doi: 10.1016/j.mce.2013.08.022.

29. Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, et al. Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol. 2021 Nov;17(11):671-84. doi: 10.1038/s41574- 021-00550-w.

30. Jones PS, Swearingen B. Pituitary surgery in Cushing's disease: first line treatment and role of reoperation. Pituitary. 2022 Oct;25(5):713-7. doi: 10.1007/s11102-022-01254-8.

31. Bello MO, Garla VV. Gigantism and acromegaly. [Updated 2021 Dec 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih. gov/books/NBK538261/. [Accessed 30th November 2022].

32. Sheely D, Pujare D. Endocrinopathies. Med Clin North Am. 2022 May;106(3):495-507. doi: 10.1016/j.mcna.2021.12.010.

33. Zubair A, M Das JM. Transsphenoidal hypophysectomy. 2022 Jun

27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. PMID: 32310602.

34. Chen J, Liu H, Man S, Liu G, Li Q, Zuo Q, et al. Endoscopic vs.

microscopic transsphenoidal surgery for the treatment of pituitary adenoma: a meta-analysis. Front Surg. 2022 Feb 2;8:806855. doi: 10.3389/fsurg.2021.806855. VERTE^

35. Byun YH, Kang H, Kim YH. Advances in pituitary surgery. Endocrinol Metab (Seoul). 2022 Aug;37(4):608-16. doi: 10.3803/ EnM.2022.1546.

36. Караченцев ЮІ, Кравчун НО, Місюра КВ. Стан ендокринологічної науки та перспективи її розвитку в державній установі «Інститут проблем ендокринної патології ім. В.Я. Данилевсько- го НАМН України» (до 100-річчя від дня існування). Пробл. ендокрин. патол. 2019 Листопад 11;(4):7-13 (Karachentsev Yu, Kravchun N, Misiura K. Status ofendocrinological science and prospects for its development in State Institution «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine» (to the 100th anniversary of its foundation). Probl Endocrin Pathol. 2019 Nov 11;(4):7-13). Ukrainian. doi: 10.21856/j-PEP.2019.4.01.

37. Тронько МД, Караченцев ЮІ, Кваченюк АМ, Хижняк ОО, Гук МО, Возняк ОМ, та ін. Проблема акромегалії в Україні. Створення Всеукраїнського національного реєстру хворих на акромегалію та аналіз попередніх даних. Ендокринологія. 2022 Червень 30;27(2):96-105 (Tronko MD, Karachentsev YuI, Kvachenyuk AM, Khyzhnyak OO, Huk MO, Voznyak OM, et al. The problem of acromegalia in Ukraine. Creation of the allUkrainian national register of acromegaly patients and analysis of previous data. Endokrynologia. 2022 Jun 30;27(2):96-105). Ukrainian. doi: 10.31793/1680-1466.2022.27-2.96.

38. Jayasinghe R, Basnayake O, Jayarajah U, Seneviratne S. Management of medullary carcinoma of the thyroid: a review. J Int Med Res. 2022 Jul;50(7):3000605221110698. doi: 10.1177/03000605221110698.

39. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun;25(6):567-610. doi: 10.1089/thy.2014.0335.

40. Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Dec 1;30(12):1856-83. doi: 10.1093/annonc/mdz400.

41. Ito Y, Onoda N, Okamoto T. The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: core questions and recommendations for treatments of thyroid cancer. Endocr J. 2020 Jul 28;67(7):669-717. doi: 10.1507/endocrj.EJ20-0025.

42. Haddad RI, Bischoff L, Ball D, Bernet V, Blomain E, Busaidy NL, et al. Thyroid carcinoma, version 2.2022, NCCN Clinical Practice Guidelines in oncology. J Natl Compr Canc Netw. 2022 Aug;20(8):925-51. doi: 10.6004/jnccn.2022.0040.

43. Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab. 2010 Jun;95(6):2655-63. doi: 10.1210/jc.2009-2368.

44. Tuttle RM. Medullary thyroid cancer: surgical treatment and prognosis: 2020. Available from: https://www.uptodate. com/contents/medullary-thyroid-cancer-surgical-treatment- and-prognosis?search = Medullary%20thyroid%20carcinoma& source = search_result&selectedTitle = 2 ~ 86&usage_ type=default&display_rank=2 [Accessed 30th November 2022].

45. Dralle H, Musholt TJ, Schabram J, Steinmuller T, Frilling A, Simon D, et al. German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg. 2013 Mar;398(3):347-75. doi: 10.1007/s00423-013-1057-6.

46. Machens A, Dralle H. Surgical treatment of medullary thyroid cancer. Recent Results Cancer Res. 2015;204:187-205. doi: 10.1007/978-3-319-22542-5_9.

47. Kuo EJ, Sho S, Li N, Zanocco KA, Yeh MW, Livhits MJ. Risk factors associated with reoperation and disease-specific mortality in patients with medullary thyroid carcinoma. JAMA Surg. 2018 Jan 1;153(1):52-9. doi: 10.1001/jamasurg.2017.3555.

48. Konstantinidis A, Stang M, Roman SA, Sosa JA. Surgical management of medullary thyroid carcinoma. Updates Surg. 2017 Jun;69(2):151-60. doi: 10.1007/s13304-017-0443-y.

49. Valerio L, Cantara S, Puxeddu E, Castagna MG. Editorial: Non- syndromic familial non-medullary thyroid carcinoma: clinical and genetic update. Front Endocrinol (Lausanne). 2022 Apr 6;13:891903. doi: 10.3389/fendo.2022.891903.

50. Kamani T, Charkhchi P, Zahedi A, Akbari MR. Genetic susceptibility to hereditary non-medullary thyroid cancer. Hered Cancer Clin Pract. 2022 Mar 7;20(1):9. doi: 10.1186/s13053-022- 00215-3.

51. Wang X, Cheng W, Li J, Su A, Wei T, Liu F, et al. Endocrine tumours: familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis. Eur J Endocrinol. 2015 Jun;172(6):R253- R262. doi: 10.1530/EJE-14-0960.

52. El Lakis M, Giannakou A, Nockel PJ, Wiseman D, Gara SK, Patel D, et al. Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment. Surgery. 2019 Jan;165(1):50-7. doi: 10.1016/j.surg.2018.05.075.

53. Capezzone M, Robenshtok E, Cantara S, Castagna MG. Familial non-medullary thyroid cancer: a critical review. J Endocrinol Invest. 2021 May;44(5):943-50. doi: 10.1007/s40618-020-01435-x.

54. Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012 Nov;22(11):1104-39. doi: 10.1089/thy.2012.0302.

55. Greenberg JA, Moore MD, Thiesmeyer JW, Egan CE, Lee YJ, Christos P, et al. Coexisting papillary and anaplastic thyroid cancer: elucidating the spectrum of aggressive behavior. Ann Surg Oncol. 2022 Oct 12. doi: 10.1245/s10434-022-12553-6.

56. Zivaljevic V, Tausanovic K, Paunovic I, Diklic A, Kalezic N, Zoric G, et al. Age as a prognostic factor in anaplastic thyroid cancer. Int J Endocrinol. 2014;2014:240513. doi: 10.1155/2014/240513.

57. Tiedje V, Ting S, Herold T, Synoracki S, Latteyer S, Moeller LC, et al. NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma. Oncotarget. 2017 Jun 27;8(26):42613-20. doi: 10.18632/oncotarget.17300.

58. Goffredo P, Thomas SM, Adam MA, Sosa JA, Roman SA. Impact of timeliness of resection and thyroidectomy margin status on survival for patients with anaplastic thyroid cancer: an analysis of 335 cases. Ann Surg Oncol. 2015 Dec;22(13):4166-74. doi: 10.1245/s10434-015-4742-6.

59. Jarzqb B, Dedecjus M, Slowinska-Klencka D, Lewinski A, Adamczewski Z, Anielski R, et al. Guidelines of Polish National Societies Diagnostics and Treatment of Thyroid Carcinoma. 2018 Update. Endokrynol Pol. 2018;69(1):34-74. doi: 10.5603/ EP.2018.0014.

60. Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC. Multimodality treatment for anaplastic thyroid carcinoma -- treatment outcome in 75 patients. Radiother Oncol. 2009 Jul;92(1):100-4. doi: 10.1016/j.radonc.2009.02.016.

61. Tiedje V, Stuschke M, Weber F, Dralle H, Moss L, Fuhrer D. Anaplastic thyroid carcinoma: review of treatment protocols. Endocr Relat Cancer. 2018 Mar;25(3):R153-R161. doi: 10.1530/ERC-17-0435.

62. Brignardello E, Palestini N, Felicetti F, Castiglione A, Piovesan A, Gallo M, et al. Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012. Thyroid. 2014 Nov;24(11):1600-6. doi: 10.1089/thy.2014.0004.

63. Bilezikian JP, BandeiraL, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018 Jan 13;391(10116):168-78. doi: 10.1016/S0140- 6736(17)31430-7.

64. Mazotas IG, Yen TWF, Doffek K, Shaker JL, Carr AA, Evans DB, et al. Persistent/recurrent primary hyperparathyroidism: does the number of abnormal glands play a role? J Surg Res. 2020 Feb;246:335-41. doi: 10.1016/j.jss.2019.08.007.

65. Papavramidis TS, Chorti A, Pliakos I, Panidis S, Michalopoulos A. Parathyroid cysts: a review of 359 patients reported in the international literature. Medicine (Baltimore). 2018 Jul;97(28):e11399. doi: 10.1097/MD.0000000000011399.

66. Gorbacheva AM, Eremkina AK, Mokrysheva NG. [Hereditary syndromal and nonsyndromal forms of primary hyperparathyroidism]. Probl Endokrinol (Mosk). 2020 Aug 4;66(1):23-34. Russian. doi: 10.14341/probl10357.

67. Marx SJ, Lourenjo DM Jr. Familial hyperparathyroidism -- disorders of growth and secretion in hormone-secretory tissue. Horm Metab Res. 2017 Nov;49(11):805-15. doi: 10.1055/s-0043-120670.

68. Cetani F, Saponaro F, Borsari S, Marcocci C. Familial and hereditary forms of primary hyperparathyroidism. Front Horm Res. 2019;51:40-51. doi: 10.1159/000491037.

69. Cristina EV, Alberto F. Management of familial hyperparathyroidism syndromes: MEN1, MEN2, MEN4, HPT-Jaw tumour,

familial isolated hyperparathyroidism, FHH, and neonatal severe hyperparathyroidism. Best Pract Res Clin Endocrinol Metab. 2018 Dec;32(6):861-75. doi: 10.1016/j.beem.2018.09.010.

70. Zammit M, Pierce K, Bailey L, Rowland M, Waghorn A, Shore S. Challenging NICE guidelines on parathyroid surgery. Surgeon. 2022 Aug;20(4):e105-e111. doi: 10.1016/j.surge.2021.04.008.

71. Mogl MT, Goretzki PE. Chirurgie des hyperparathyreoidismus [Surgery of hyperparathyroidism]. Chirurgie (Heidelb). 2022 Jun 1. German. doi: 10.1007/s00104- 022-01652-5.

72. Kowalski G, Bula G, Bednarczyk A, Gawrychowska A, Gawrychowski J. Multiglandular parathyroid disease. Life (Basel). 2022 Aug 22;12(8):1286. doi: 10.3390/life12081286.

73. Iacobone M, Citton M, Viel G, Schiavone D, Torresan F. Surgical approaches in hereditary endocrine tumors. Updates Surg. 2017 Jun;69(2):181-91. doi: 10.1007/s13304-017-0451-y.

74. Ryhanen EM, Leijon H, Metso S, Eloranta E, KorsoffP, Ahtiainen P, et al. A nationwide study on parathyroid carcinoma. Acta Oncol. 2017 Jul;56(7):991-1003. doi: 10.1080/0284186X.2017.1306103.

75. Bollerslev J, Schalin-Jantti C, Rejnmark L, Siggelkow H, Morreau H, Thakker R, et al. Management of endocrine disease: unmet therapeutic, educational and scientific needs in parathyroid disorders. Eur J Endocrinol. 2019 Sep 1;181(3):P1-P19. doi: 10.1530/EJE-19-0316.

76. Cetani F, Pardi E, Marcocci C. Update on parathyroid carcinoma. J Endocrinol Invest. 2016 Jun;39(6):595-606. doi: 10.1007/s40618- 016-0447-3.

77. Carling T, Udelsman R. Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med. 2005 Jan;257(1):27-37. doi: 10.1111/j.1365-2796.2004.01428.x.

78. VanderWalde LH, Haigh PI. Surgical approach to the patient with familial hyperparathyroidism. Curr Treat Options Oncol. 2006 Jul;7(4):326-33. doi: 10.1007/s11864-006-0042-5.

79. Kaszczewska M, Popow M, Chudzinski W, Kaszczewska J, Bogdanska M, Podgorska J, et al. A woman with a 27-year history of hyperparathyroidism and hypercalcemia who was diagnosed with low-grade parathyroid carcinoma. Am J Case Rep. 2021 Mar 11;22:e930301. doi: 10.12659/AJCR.930301.

80. Schulte KM, Talat N. Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol. 2012 Oct;8(10):612-22. doi: 10.1038/ nrendo.2012.102.

81. Machado NN, Wilhelm SM. Parathyroid cancer: a review. Cancers (Basel). 2019 Oct 28;11(11):1676. doi: 10.3390/cancers11111676.

82. Kowalski GJ, Bednarczyk A, Bula G, Gawrychowska A, Gawrychowski J. Parathyroid carcinoma -- a study of 29 cases. Endokrynol Pol. 2022;73(1):56-63. doi: 10.5603/EP.a2022.0003.

83. Storvall S, Ryhanen E, Bensch FV, Heiskanen I, Kytola S, Ebeling T, et al. Recurrent metastasized parathyroid carcinoma- long-term remission after combined treatments with surgery, radiotherapy, cinacalcet, zoledronic acid, and temozolomide. JBMR Plus. 2018 Nov 29;3(4):e10114. doi: 10.1002/jbm4.10114.

84. Kotova IV, Britvin TA, Beloshitskiy ME. The difficult situation in parathyroid surgery. Probl Endocrin Pathol. 2018 Aug 18;64(2):21- 4. Russian. doi: 10.21856/j-PEP.2018.2.03.

85. Десятерик ВІ, Міхно СП, Поліщук ЛМ, Залозний ОВ. Проблеми пізньої діагностики первинного гіперпаратиреозу. Шпитальна хірургія. Журнал імені Л.Я. Ковальчука. 2017 Листопад 08;(3):63-8 (Desiateryk VI, Mikhno SP, Polischuk LM, Zaloznyi OV. Problems of different diagnostics of the primary hyperparathyreosis. Hospital surgery. J by LYa Kovalchuk. 2017 Nov 08;(3):63-8). Ukrainian. doi: 10.11603/24144533.2017.3.8020.

86. Eckstein N, Haas B, Hass MD, Pfeifer V. Systemic therapy of Cushing's syndrome. Orphanet J Rare Dis. 2014 Aug 5;9:122. doi: 10.1186/s13023-014-0122-8.

87. Ragnarsson O, Johannsson G. Cushing's syndrome: a structured short- and long-term management plan for patients in remission. Eur J Endocrinol. 2013 Oct 4;169(5):R139- R152. doi: 10.1530/ EJE-13-0534.

88. Gustafsson BI, Kidd M, Chan A, Malfertheiner MV, Modlin IM. Bronchopulmonary neuroendocrine tumors. Cancer. 2008 Jul 1;113(1):5-21. doi: 10.1002/cncr.23542.

89. Shahani S, Nudelman RJ, Nalini R, Kim HS, Samson SL. Ectopic corticotropin-releasing hormone (CRH) syndrome from metastatic small cell carcinoma: a case report and review of the literature.

Diagn Pathol. 2010 Aug 31;5:56. doi: 10.1186/1746-1596-5-56.

90. Libe R, Horvath A, Vezzosi D, Fratticci A, Coste J, Perlemoine K, et al. Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype. J Clin Endocrinol Metab. 2011 Jan;96(1):E208-E214. doi: 10.1210/jc.2010-1704.

91. Maghrabi A, Yaqub A, Denning KL, Benhamed N, Faiz S, Saleem T. Challenges in the diagnostic work-up and management of patients with subclinical Cushing's syndrome and bilateral adrenal masses. Endocr Pract. 2013 May-Jun;19(3):515-21. doi: 10.4158/ EP12277.RA.

92. Arezzo A, Bullano A, Cochetti G, Cirocchi R, Randolph J, Mearini E, et al. Transperitoneal versus retroperitoneal laparoscopic adrenalectomy for adrenal tumours in adults. Cochrane Database Syst Rev. 2018 Dec 30;12(12):CD011668. doi: 10.1002/14651858. CD011668.pub2.

93. Dubaj M, Dembowska A, Bigosinski K. Adrenal incidentaloma (AI) -- a puzzle not only for an endocrinologist. J Educ Health Sport. 2022 Jul 25;12(7):730-9. doi: 10.12775/JEHS.2022.12.07.071.

94. James BC, Aschebrook-Kilfoy B, Cipriani N, Kaplan EL, Angelos P, Grogan RH. The incidence and survival of rare cancers of the thyroid, parathyroid, adrenal, and pancreas. Ann Surg Oncol. 2016 Feb;23(2):424-33. doi: 10.1245/s10434-015-4901-9.

95. Jasim S, Habra MA. Management of adrenocortical carcinoma. Curr Oncol Rep. 2019 Feb 23;21(3):20. doi: 10.1007/s11912-019- 0773-7.

96. Sandru F, Petca RC, Carsote M, Petca A, Dumitrascu MC, Ghemigian A. Adrenocortical carcinoma: Pediatric aspects (Review). Exp Ther Med. 2022 Apr;23(4):287. doi: 10.3892/ etm.2022.11216.

97. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012 Jun 7;366(23):2189-97. doi: 10.1056/NEJMoa1200966.

98. Head L, Kiseljak-Vassiliades K, Clark TJ, Somerset H, King J, Raeburn C, et al. Response to immunotherapy in combination with Mitotane in patients with metastatic adrenocortical cancer.

J Endocr Soc. 2019 Oct 11;3(12):2295-304. doi: 10.1210/js.2019- 00305.

99. Jimenez C, Armaiz-Pena G, Dahia PLM, Lu Y, Toledo RA, Varghese J, et al. Endocrine and neuroendocrine tumors special issue-checkpoint inhibitors for adrenocortical carcinoma and metastatic pheochromocytoma and paraganglioma: do they work? Cancers (Basel). 2022 Jan 18;14(3):467. doi: 10.3390/ cancers14030467.

100. Neumann HPH, Tsoy U, Bancos I, Amodru V, Walz MK, Tirosh A, et al. Comparison of pheochromocytoma-specific morbidity and mortality among adults with bilateral pheochromocytomas undergoing total adrenalectomy vs cortical-sparing adrenalectomy. JAMA Netw Open. 2019 Aug 2;2(8):e198898. doi: 10.1001/jamanetworkopen.2019.8898.

101. Zhang Z, Ye Y, Yu J, Liao S, Pan W, Guo Y, et al. A nomogram for predicting intraoperative hemodynamic instability in patients with pheochromocytoma. Front Endocrinol (Lausanne). 2022 Jan 6;12:787786. doi: 10.3389/fendo.2021.787786.

102. Lyu T, Niu J, Liu Z, Li T. Case report: early resection of pheochromocytoma in a patient with cardiogenic shock due to pheochromocytoma-induced cardiomyopathy with extracorporeal life support. Front Cardiovasc Med. 2022 Mar 21;9:788644. doi: 10.3389/fcvm.2022.788644.

103. Hsieh SJ, Chung SD, Chen KH. Laparoscopic adrenalectomy with

partial hepatectomy for a locally advanced pheochromocytoma. Asian J Surg. 2022 Apr;45(4):1080-1. doi: 10.1016/j.

asjsur.2022.01.065.

104. RzepkaE,KokoszkaJ, GrochowskaA,Ulatowska-Bialas M,Lech M, Opalinska M, et al. Adrenal bleeding due to pheochromocytoma -- A call for algorithm. Front Endocrinol (Lausanne). 2022 Aug 5;13:908967. doi: 10.3389/fendo.2022.908967.

105. Хижняк ОО, Барабаш НЄ, Микитюк МР, Ніколаєв РС, Ман- ська КГ, Тихонова ТМ. Епідеміологія акромегалії: Сучасний стан проблеми (огляд літератури та власні дані). Пробл ен- докрин патол. 2018 Серпень 29;65(3):67-74 (Khizhnyak OO, VERTE >

Перспективи ендокринології

Barabash NE, Mikityuk MR, Nikolaev RS, Manskaya EH, Tikhonova TM. Epidemiology of acromegaly: current state of the problem (review of literature and own data). Probl Endocrin Pathol. 2018 Aug 29;65(3):67-74). Ukrainian. doi: 10.21856/j-PEP.2018.3.08.

106. CSD Lab. Ukrainian. Available from: https://www.csdlab.ua/ru/ analyzes/inshe-0 [Accessed 30th November 2022].

107. Кабінет Міністрів України. Про схвалення Концепції розвитку системи надання медичної допомоги пацієнтам, які страждають на рідкісні (орфанні) захворювання, на 2021-2026 роки. Розпорядження від 28.04.2021 № 377-р. (Cabinet of Ministers of Ukraine. On the approval of the Concept for the development of the system of providing medical care to patients suffering from rare (orphan) diseases for 2021-2026. Order N 377 dated 04.28.2021). Ukrainian. Available from: https://zakon.rada.gov.ua/laws/ show/377-2021-%D1%80#Text. [Accessed 30th November 2022].

108. Міністерство охорони здоров'я України. Про забезпечення розширеного неонатального скринінгу в Україні. Наказ від 01.10.2021 №2142 (Ministry of Health of Ukraine. On provision of extended neonatal screening in Ukraine. Order N 2142 dated 01.10.2021). Ukrainian. Available from: https://zakon.rada.gov. ua/laws/show/z1403-21#Text. [Accessed 30th November 2022].

Список скорочень

АК -- анапластична карцинома

АКК -- адренокортикальна карцинома

КЦ -- кальцитонін

ЩЗ -- щитоподібна залоза

МК -- медулярна карцинома

ПГПТ -- первинний гіпопаратиреоз

ПЩЗ -- прищитовидні залози

СНМР -- сімейний немедулярний рак

ФЕО -- феохромоцитома

MEN -- синдром множинної ендокринної неоплазії

Размещено на Allbest.ru

...

Подобные документы

Работы в архивах красиво оформлены согласно требованиям ВУЗов и содержат рисунки, диаграммы, формулы и т.д.
PPT, PPTX и PDF-файлы представлены только в архивах.
Рекомендуем скачать работу.